IN CONVERSATION WITH RAHUL BISHNOI CHAIRMAN, MEDICAMEN BIOTECH LIMITED

• Year: 2018
• January 01, 2022

Medicamen Oncology Products

Launch Date: January 1, 2022

Medicamen Biotech Limited (MBL) has been exporting pharmaceutical products since its inception in 1996. In a major development, we have established a US-compliant ONCO formulation facility in Haridwar. We are strategically launching oncology products in the domestic market with the goal of offering global-quality oncology treatments at affordable prices. This will help reduce the “Out of Pocket Expense” for quality cancer care in India.

Our focused approach in the oncology space includes novel targeted therapies for the treatment of solid tumors and hematology cancers.

Domestic Market Opportunity

The total domestic market size for oncology drugs is approximately Rs. 5000 crores, with a 5-year CAGR (expected growth) of 12%. Although the annual segment growth is currently only 7% due to the nationwide lockdown during the COVID-19 pandemic, targeted therapy contributes 50% of the market pie and is the main growth driver. This segment is growing at 12.5% and is projected to exceed 20% growth in the next three years.

Key Growth Drivers

1. Product and Technology: Backed by experienced R&D and a patient-centric approach, we focus on providing affordable and quality cancer care.
2. Targeted Therapy Segment: Developing and launching products for high-incidence cancers such as breast, lung, and hematological cancers.
3. Indian Branded Generics: Launching the first Indian branded generics in oncology with in-house R&D, API, and manufacturing expertise for domestic and South-East Asian markets.

Our strengths are well-aligned with market opportunities, positioning us to achieve significant growth.

Expansion Plans (Next 3 Years)

• File at least two ANDAs next year for oncology products in regulated markets.
• Develop 10 R&D products for regulated markets like Australia and the EU.
• Focus on supportive care in oncology by manufacturing products to manage chemotherapy side effects.

R&D Investments

Since 2018, we have invested Rs. 15 crores in establishing a state-of-the-art R&D facility at our Bhiwadi campus. This 6000 sq. ft. facility has grown to 12,000 sq. ft. with an additional Rs. 15 crore investment. Our R&D team, led by Dr. Akshay Kant Chaturvedi, includes 60 experienced scientists and is fully capable of handling para-4 filings.

Top 3 Strategic Initiatives

1. Transforming lives of cancer patients by increasing access to affordable, global-quality oncology products in India.
2. Leveraging R&D capabilities to innovate drug delivery systems and develop novel targeted therapies.
3. Filing core oncology products (ANDAs).

Key Risks

1. Overall cancer therapy market growth remains lower due to the pandemic, which will take 1-2 years to stabilize.
2. Procurement processes for new hospital formularies are delayed, with older products still in use.